Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies.
The pharmacokinetics of imipenem/cilastatin were studied in febrile neutropenic patients with haematological malignancies. The peak plasma concentrations (36.4 +/- 4.96 mg/l), plasma half-life (60 min), volume of distribution (0.28 +/- 0.02 l/kg) and plasma clearance (3.23 +/- 0.38 ml/min/kg) were comparable with those in normal healthy volunteers suggesting that the drug handling is not appreciably altered in this group of patients. The administration of 12.5 mg/kg (max 1 g), 6-hourly achieved levels that were up to 3.5 times MICs of most relevant bacteria. The drug therefore has a potential use as empirical monotherapy in febrile neutropenic patients.
Janmohamed
R M
RM
Department of Haematology, East Birmingham Hospital, UK.
Leyland
M J
MJ
Kelly
J
J
Farrell
I
I
D000208:Acute Disease; D000328:Adult; D000380:Agranulocytosis / Q000378:metabolism*; D001793:Blood Preservation; D002851:Chromatography, High Pressure Liquid; D015377:Cilastatin / Q000493:pharmacokinetics*; D000077728:Cilastatin, Imipenem Drug Combination; D004338:Drug Combinations / Q000493:pharmacokinetics; D004359:Drug Therapy, Combination / Q000493:pharmacokinetics; D005260:Female; D006207:Half-Life; D006801:Humans; D015378:Imipenem / Q000493:pharmacokinetics*; D007938:Leukemia / Q000150:complications / Q000378:metabolism*; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009503:Neutropenia / Q000209:etiology / Q000378:metabolism*
D004338:Drug Combinations; D015377:Cilastatin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination